Phillipe Follana

6PUBLICATIONS
79CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 08, 2026
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial.

Félix Blanc-Durand, Catherine Genestie, Sergey Nikolaev

|Dec 03, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.

Philipp Harter, Frederik Marmé, Andrés Redondo

|Sep 23, 2025
Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial.

Séverine Guiu, Judith Balmaña, Pablo Lemercier

|Aug 26, 2025
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial.

Florence Joly, Alexandra Leary, Isabelle Ray-Coquard

|Dec 14, 2024
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe).

Florence Joly, Fernando Bazan, Delphine Garbay

|Mar 27, 2023
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects.

Mansoor Raza Mirza, Gabriel Lindahl, Sven Mahner

Pageof 1

Frequent Collaborators

4 joint publications

Frédéric Selle

3 joint publications

Florence Joly

3 joint publications

Coriolan Lebreton

3 joint publications

Elise Bonnet